Biomarker ID | 1887 |
PMID | 30623593 |
Year | 2018 |
Biomarker | Ig heavy chain Vâ€III region BRO; Alphaâ€1â€antitrypsin; Plasminogen (0.1†fold); Ig heavy chain Vâ€III region TIL, Hemopexin; Afamin; Interâ€alphaâ€trypsin inhibitor heavy chain H1; Protein AMBP; Alphaâ€1Bâ€glycoprotein; Complement component C8 alpha chain; |
Biomarker Basis | Concentration Based |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in PCa [Alphaâ€1â€acid glycoprotein 1 (13.6â€fold); Alphaâ€1Bâ€glycoprotein (11.6â€fold); von Willebrand factor (5.0â€fold); Ig heavy chain Vâ€II region NEWM (6.0â€fold); Ig heavy chain Vâ€III region BRO (5.7â€fold); Afamin (5.4â€fold); Apolipoprotein Aâ€I (4.9â€fold); Isoform 3 of Vitamin Dâ€binding protein (4.3â€fold); Complement C1r subcomponent (4.3†fold); Angiotensinogen (4.1â€fold); |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | African American men with PCa (PAA) Vs Caucasian men with PCa (PCC) |
Type of Biomarker | Diagnostic |
Cohort | Serum samples from African American and Caucasian PCa patients and matched healthy donors were collected after patients’ consents |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | mass spectrometry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |